Table 4

Unadjusted and adjusted effect of supplemental oxygen exposure (per every 100 L increase in the first 12 h) on biochemical and CMR measures of myocardial infarct size

Outcome measureUnadjusted estimate (95% CI)*p ValueAdjusted estimate 1 (95% CI)*†p ValueAdjusted estimate 2 (95% CI)†‡p ValueAdjusted estimate 3 (95% CI)†§p ValueAdjusted estimate 4 (95% CI)†¶p Value
Logarithm peak cTnI0.018 (0.011 to 0.026)<0.0010.014 (0.006 to 0.022)<0.0010.015 (0.002 to 0.027)0.020.012 (0.002 to 0.021)0.010.011 (0.001 to 0.023)0.04
Logarithm AUC72 cTnI0.019 (0.011 to 0.026)<0.0010.013 (0.006 to 0.021)<0.0010.014 (0.002 to 0.026)0.020.012 (0.004 to 0.021)0.0060.012 (0.002 to 0.023)0.02
Logarithm peak CK0.016 (0.010 to 0.022)<0.0010.012 (0.007 to 0.018)<0.0010.011 (0.002 to 0.020)0.010.010 (0.003 to 0.017)0.0030.010 (0.002 to 0.018)0.01
Logarithm AUC72 CK0.013 (0.008 to 0.019)<0.0010.010 (0.005 to 0.015)<0.0010.008 (0.001 to 0.016)0.040.008 (0.003 to 0.014)0.0050.007 (0.001 to 0.014)0.03
Logarithm CMR infarct mass (g)**0.014 (0.004 to 0.024)0.0050.012 (0.001 to 0.023)0.030.010 (−0.006 to 0.027)0.210.011 (−0.001 to 0.024)0.080.005 (−0.011 to 0.021)0.57
Logarithm CMR infarct percent (%)**0.012 (0.003 to 0.021)0.0070.009 (0.001 to 0.019)0.060.005 (−0.010 to 0.020)0.520.009 (−0.002 to 0.021)0.110.003 (−0.011 to 0.017)0.71
  • *Primary analysis includes all patients with available data (n=441).

  • †Model adjusted for the following covariates: age, gender, diabetes, smoker status, hypertension, culprit artery, Killip class, preintervention and postintervention thrombolysis in myocardial infarction (TIMI) flow, procedural complication and symptom-to-intervention time.

  • ‡Sensitivity analysis conducted in patients randomised to the oxygen treatment arm (n=218).

  • §Sensitivity analysis excludes patients with cardiogenic shock, recurrent myocardial infarction during admission, or desaturations (SpO2<94%) at any time (n=325).

  • ¶Sensitivity analysis excludes all patients with any adverse clinical event at discharge, including mortality, recurrent myocardial infarction, stroke or transient ischemic attack, cardiogenic shock, coronary artery bypass grafting, major bleeding and arrhythmia (n=258).

  • **Subgroup with available data at 6 months (n=139).

  • CK, creatine kinase; CMR, cardiac MRI; cTnI, Troponin I.